Plasma DNA Methylation‐Based Biomarkers for MPNST Detection in Patients With Neurofibromatosis Type 1
- Published on 03/07/2025
- Reading time: 6 min.
Katarzyna Tomczak 1,2, Manishkumar S. Patel 3, Angela D. Bhalla 1, Christine B. Peterson 4, Sharon M. Landers 1, S. Carson Callahan 2, Di Zhang 5, Justin Wong 5, Jace P. Landry 1, Alexander J. Lazar 6, J. Andrew Livingston 7, B. Ashleigh Guadagnolo 8, Heather G. Lyu 1, Heather Lillemoe 1, Christina L. Roland 1, Emily Z. Keung 1, Christopher P. Scally 1, Kelly K. Hunt 9, Ian E. McCutcheon 10, John M. Slopis 11, Jian Gu 5, Paul Scheet 5, Liang Wang 3, Kunal Rai 2, Keila E. Torres 1,2
1
Department of Surgical Oncology
The University of Texas MD Anderson Cancer Center
Houston
Texas
USA
2
Department of Genomic Medicine
The University of Texas MD Anderson Cancer Center
Houston
Texas
USA
3
Department of Tumor Microenvironment and Metastasis
H. Lee Moffitt Cancer Center and Research Institute
Tampa
Florida
USA
4
Department of Biostatistics
The University of Texas MD Anderson Cancer Center
Houston
Texas
USA
5
Department of Epidemiology
The University of Texas MD Anderson Cancer Center
Houston
Texas
USA
6
Department of Pathology
The University of Texas MD Anderson Cancer Center
Houston
Texas
USA
7
Department of Sarcoma Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston
Texas
USA
8
Department of Radiation Oncology
The University of Texas MD Anderson Cancer Center
Houston
Texas
USA
9
Department of Breast Surgical Oncology
The University of Texas MD Anderson Cancer Center
Houston
Texas
USA
10
Department of Neurosurgery
The University of Texas MD Anderson Cancer Center
Houston
Texas
USA
11
Department of Neuro‐Oncology
The University of Texas MD Anderson Cancer Center
Houston
Texas
USA
Abstract
Malignant peripheral nerve sheath tumor (MPNST) development is characterized by an altered DNA methylation landscape, which presents a promising area for developing MPNST‐specific biomarkers for screening patients with NF1. Genome‐wide DNA methylation profiling of a cohort of 13 patients with MPNST (29 samples of tumor and adjacent neurofibroma tissues) and of NF1‐MPNST cell lines was performed to identify and validate candidate MPNST‐specific CpG sites...
To continue reading this article in Full-Text...
Peer-Reviewed Journals A-Z
Search | Advanced search
Get the latest news in Rare Diseases
Receive our newsletter to stay up to date with the latest news in Rare Diseases